Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ORAL ESTRAMUSTINE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 45 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Pirtskhalaishvili, G; Hrebinko, RL; Nelson, JB
      The treatment of prostate cancer - An overview of current options

      CANCER PRACTICE
    2. Sternberg, CN
      Systemic treatment and new developments in advanced prostate cancer

      EUROPEAN JOURNAL OF CANCER
    3. Small, EJ
      Docetaxel in prostate cancer

      ANTI-CANCER DRUGS
    4. Hamilton, A; Muggia, F
      Estramustine potentiates taxane in prostate and refractory breast cancers

      ONCOLOGY-NEW YORK
    5. Obasaju, C; Hudes, GR
      Paclitaxel and docetaxel in prostate cancer

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    6. Savarese, DM; Halabi, S; Hars, V; Akerley, WL; Taplin, ME; Godley, PA; Hussain, A; Small, EJ; Vogelzang, NJ
      Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780

      JOURNAL OF CLINICAL ONCOLOGY
    7. Kelly, WK; Curley, T; Slovin, S; Heller, G; McCaffrey, J; Bajorin, D; Ciolino, A; Regan, K; Schwartz, M; Kantoff, P; George, D; Oh, W; Smith, M; Kaufman, D; Small, EJ; Schwartz, L; Larson, S; Tong, W; Scher, H
      Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

      JOURNAL OF CLINICAL ONCOLOGY
    8. Heidenreich, A; von Knobloch, R; Hofmann, R
      Current status of cytotoxic chemotherapy in hormone refractory prostate cancer

      EUROPEAN UROLOGY
    9. Kuniyasu, H; Yasui, W; Pettaway, CA; Yano, S; Oue, N; Tahara, E; Fidler, IJ
      Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells

      PROSTATE
    10. Pienta, KJ; Fisher, EI; Eisenberger, MA; Mills, GM; Goodwin, JW; Jones, JA; Dakhil, SR; Crawford, ED; Hussain, MHA
      A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology GroupTrial (SWOG 9407)

      PROSTATE
    11. Pienta, KJ
      Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer

      SEMINARS IN ONCOLOGY
    12. Beer, TM; Hough, KM; Garzotto, M; Lowe, BA; Henner, WD
      Weekly high-dose calcitriol and docetaxel in advanced prostate cancer

      SEMINARS IN ONCOLOGY
    13. Gleave, ME; Miyake, H; Zellweger, T; Chi, K; July, L; Nelson, C; Rennie, P
      Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

      UROLOGY
    14. Vaishampayan, U; Glode, M; Du, W; Kraft, A; Hudes, G; Wright, J; Hussain, M
      Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

      CLINICAL CANCER RESEARCH
    15. Morant, R; Bernhard, J; Maibach, R; Borner, M; Fey, MF; Thurlimann, B; Jacky, E; Trinkler, F; Bauer, J; Zulian, G; Hanselmann, S; Hurny, C; Hering, F
      Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma

      ANNALS OF ONCOLOGY
    16. Culine, S; Droz, JP
      Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: Adecade of progress?

      ANNALS OF ONCOLOGY
    17. Walther, PJ
      Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma

      WORLD JOURNAL OF UROLOGY
    18. Haas, NB; Manola, J; Hudes, G; Citrin, DL; Kies, MS; Davis, TE
      Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer - Eastern Cooperative OncologyGroup study PH882

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    19. Beer, T; Raghavan, D
      Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder

      PROSTATE
    20. Willman, JH; Holden, JA
      Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate

      PROSTATE
    21. Petrylak, DP
      Docetaxel (Taxotere) in hormone-refractory prostate cancer

      SEMINARS IN ONCOLOGY
    22. Carducci, MA
      Adjuvant chemotherapy for T3 prostate cancer: Not ready for prime time

      UROLOGY
    23. Small, EJ; Reese, DM
      New treatment strategies in advanced prostate cancer

      RADIOLOGIC CLINICS OF NORTH AMERICA
    24. Odrazka, K; Vanasek, J; Vaculikova, M; Stejskal, J; Filip, S
      The role of chemotherapy in prostate cancer

      NEOPLASMA
    25. Smith, MR; Kaufman, D; Oh, W; Guerin, K; Seiden, M; Makatsoris, T; Manola, J; Kantoff, PW
      Vinorelbine and estramustine in androgen-independent metastatic prostate cancer - A phase II study

      CANCER
    26. Trivedi, C; Redman, B; Flaherty, LE; Kucuk, O; Du, W; Heilbrun, LK; Hussain, M
      Weekly 1-hour infusion of paclitaxel - Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

      CANCER
    27. Dawson, NA; Conaway, M; Halabi, S; Winer, EP; Small, EJ; Lake, D; Vogelzang, NJ
      A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181

      CANCER
    28. Mashimo, T; Bandyopadhyay, S; Goodarzi, G; Watabe, M; Pai, SK; Gross, SC; Watabe, K
      Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    29. Kuyu, H; Lee, WR; Bare, R; Hall, MC; Torti, FM
      Recent advances in the treatment of prostate cancer

      ANNALS OF ONCOLOGY
    30. Gleave, ME; Bruchovsky, N; Moore, MJ; Venner, P
      Prostate cancer: 9. Treatment of advanced disease

      CANADIAN MEDICAL ASSOCIATION JOURNAL
    31. Lara, PN; Meyers, FJ
      Treatment options in androgen-independent prostate cancer

      CANCER INVESTIGATION
    32. Petrylak, DP; Macarthur, RB; O'Connor, J; Shelton, G; Judge, T; Balog, J; Pfaff, C; Bagiella, E; Heitjan, D; Fine, R; Zuech, N; Sawczuk, I; Benson, M; Olsson, CA
      Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

      JOURNAL OF CLINICAL ONCOLOGY
    33. Carducci, MA; DeWeese, TL; Nelson, JB
      Prostate-specific antigen and other markers of therapeutic response

      UROLOGIC CLINICS OF NORTH AMERICA
    34. George, DJ; Kantoff, PW
      Prognostic indicators in hormone refractory prostate cancer

      UROLOGIC CLINICS OF NORTH AMERICA
    35. Kamradt, JM; Pienta, KJ
      Current chemotherapy regimens - What oncologists are using

      UROLOGIC CLINICS OF NORTH AMERICA
    36. Savarese, D; Taplin, ME; Halabi, S; Hars, V; Kreis, W; Vogelzang, N
      A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780

      SEMINARS IN ONCOLOGY
    37. Hussain, M; Petrylak, D; Fisher, E; Tangen, C; Crawford, D
      Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group study 9916

      SEMINARS IN ONCOLOGY
    38. Small, EJ; Reese, DM; Vogelzang, NJ
      Hormone-refractory prostate cancer: An evolving standard of care

      SEMINARS IN ONCOLOGY
    39. Beedassy, A; Cardi, G
      Chemotherapy in advanced prostate cancer

      SEMINARS IN ONCOLOGY
    40. Smith, DC; Pienta, KJ
      Paclitaxel in the treatment of hormone-refractory prostate cancer

      SEMINARS IN ONCOLOGY
    41. Petrylak, DP
      Chemotherapy for advanced hormone refractory prostate cancer

      UROLOGY
    42. Scher, HI; Kelly, WMK; Zhang, ZF; Ouyang, P; Sun, M; Schwartz, M; Ding, C; Wang, WP; Horak, ID; Kremer, AB
      Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    43. Biedermann, B; Pless, M; Herrmann, R
      Chemotherapy in hormone-refractory prostate cancer

      DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    44. Pilat, MJP; Kamradt, JM; Pienta, KJ
      Hormone resistance in prostate cancer

      CANCER AND METASTASIS REVIEWS
    45. Reese, DM; Tchekmedyian, S; Chapman, Y; Prager, D; Rosen, PJ
      A phase II trial of irinotecan in hormone-refractory prostate cancer

      INVESTIGATIONAL NEW DRUGS


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 12:49:46